COPD Expert Opinions

Ian Pavord

Meet the expert

Ian Pavord

Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci, is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He was an inaugural Fellow of ERS in 2014 and became a Fellow of the Academy of Medical Science in 2015. Prof. Pavord has a research interest in the clinical aspects of inflammatory airway diseases and has pioneered the use of non-invasive measures of airway inflammation. He has identified several clinically important phenotypes of inflammatory airway disease, discovered clinically important biomarkers, and played a lead role in the clinical development of 3 treatments for severe airway disease.

Disclosures:

Professor Pavord has received honoraria for speaking at sponsored meetings from Aerocrine, AstraZeneca, Almirall, Boehringer Inglehiem, Chiesi, GlaxoSmithKline, Novartis, Menarini, Sanofi and Regeneron, and Teva Pharmaceuticals, and payments for organizing educational events from AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron, and Teva Pharmaceuticals. Professor Pavord has received honoraria for attending advisory panels with AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Novartis, Merck, Sanofi and Regeneron, and Teva Pharmaceuticals, and payments to support FDA approval meetings from GlaxoSmithKline. Professor Pavord has received sponsorship to attend international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Teva Pharmaceuticals. Professor Pavord has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. Professor Pavord is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Bayer, Insmed, and Merck. In 2014–5 he was an expert witness for a patent dispute involving AstraZeneca and Teva Pharmaceuticals. 

Michael Wechsler

Meet the expert

Michael Wechsler

Michael E. Wechsler, MD, MMSc, is Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at National Jewish Health (NJH) in Denver; Director of the NJH/Cohen Family Asthma Institute; and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary and critical care medicine, Dr. Wechsler’s research focuses on clinical and translational asthma with an emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis, (i.e. Churg-Strauss syndrome [CSS]).

Disclosures:

Dr. Wechsler has received consulting honoraria from AstraZeneca, Equillium, Gala Therapeutics, GlaxoSmithKline, Genzyme, Mylan, Pulmatrix, Regeneron, Restorbio, Sanofi, Sentien Biotechnologies, and Teva Pharmaceuticals.

Nicola Hanania

What Is the COPD Vicious Cycle?

Dr. Nicola Hanania explains the vicious cycle of exacerbations and lung function decline observed in COPD

Meet the expert

Nicola Hanania

Nicola (Nick) A. Hanania, MD, MS, is professor of medicine in the Section of Pulmonary and Critical Care Medicine and director of the Airways Clinical Research Center at Baylor College of Medicine in Houston, Texas. He also serves on the Faculty Senate at Baylor College of Medicine. He is the Chief of Section of Pulmonary, Critical Care and Sleep Medicine at Ben Taub Hospital in Houston. He completed his medical training at the University of Jordan in Amman, Jordan, followed by a residency in internal medicine and a fellowship in pulmonary medicine at the University of Toronto, Toronto, Canada. He subsequently completed a fellowship in critical care medicine at Baylor College of Medicine, where he later earned a master’s degree in clinical investigation.

Dr Hanania has received multiple awards, including the ACCP’s Distinguished Scholar in Respiratory Health, Baylor College of Medicine Master Clinician Award, ACCP distinguished CHEST educator (DCE), ACCP Humanitarian Award, Career Investigator Award (K23) from the National Institutes of Health, Fulbright and Jaworski’s Faculty Excellence Award for Teaching and Evaluation, and the Award for Excellence in Teaching from the Department of Medicine at Baylor College of Medicine. He is editor-in-chief of Respiratory Medicine and is associate editor of the journals Current Opinion in Pulmonary Medicine (Asthma Section), and Lung. He serves on the editorial board of Therapeutic Advances in Respiratory Disease, Pulmonary Pharmacology and Therapeutics, and COPD (J of COPD Foundation).

Dr Hanania’s research interests focus on the pharmacology and management of asthma and COPD. He has published more than 320 peer-reviewed papers, book chapters, editorials, and reviews on these topics. His research has been funded by NIH, ALA and industry, and focuses on clinical trials investigating novel treatments. He is principal investigator for the American Lung Association Airways Clinical Research Center and COPD Gene study at Baylor College of Medicine, as well as principal investigator or co-investigator in several clinical trials in asthma and COPD. Dr Hanania has been invited and has lectured widely at local, regional, national, and international meetings.

Advisor/Consultant:

• Roche (Genentech), AstraZeneca, Boehringer Ingelheim, Novartis, GSK, Sanofi/Regeneron, Teva, Amgen, Verona Pharma

Research grant support (to institution):

• National Heart, Lung, and Blood Institute; American Lung Association
• GSK, Boehringer Ingelheim, Genentech, AstraZeneca, Sanofi, Gossamer Bio, Novartis

Editor-in-Chief

• Respiratory Medicine